Severe tricuspid regurgitation represents a prevalent and historically undertreated valvular disorder associated with substantial morbidity and mortality. For decades, clinicians managed severe regurgitation primarily with diuretic therapy because isolated surgery carried prohibitive operative risks. However, recent technological advancements have transformed the clinical paradigm. In particular, transcatheter tricuspid valve replacement has emerged as a transformative option for high-risk surgical patients. This minimally invasive intervention eliminates regurgitant volume, relieves systemic congestion, and meaningfully improves functional quality of life across complex patient cohorts.

The Clinical Burden of Severe Tricuspid Regurgitation

Tricuspid regurgitation affects millions of patients worldwide, predominantly elderly individuals with chronic atrial fibrillation or left-sided heart disease. Pathologically, chronic volume overload causes progressive annular dilation, right ventricular enlargement, and leaflet malcoaptation. Consequently, patients develop debilitating right-sided heart failure symptoms, such as peripheral edema, hepatic congestion, and ascites. Furthermore, persistent venous hypertension triggers progressive cardio-renal and cardio-hepatic impairment, which markedly worsens long-term clinical prognosis.

Historically, high surgical mortality prevented routine operative referral for isolated tricuspid disease. Medical therapy with loop diuretics offers symptomatic decongestion but fails to address the underlying annular defect. While transcatheter edge-to-edge repair helps select anatomies, severe leaflet tethering and massive coaptation gaps limit its overall success. In addition, uncorrected regurgitation promotes right ventricular remodeling and progressive functional deterioration. Therefore, definitive transcatheter replacement addresses a critical unmet therapeutic need.

Mechanism of Transcatheter Tricuspid Valve Replacement

Transcatheter tricuspid valve replacement provides an orthotopic solution designed to eliminate regurgitant flow completely. Unlike repair techniques that approximate native leaflets, replacement prostheses anchor directly within the dilated tricuspid annulus. Consequently, this intervention restores definitive valve competence regardless of preexisting leaflet tethering or large coaptation gaps.

Engineering tricuspid replacement devices presented formidable challenges due to the non-planar annulus, absence of calcium, and adjacent conduction tissue. However, innovative designs overcome these hurdles using self-expanding nitinol frames, subvalvular anchors, and atrial sealing skirts. Modern systems achieve stable fixation while minimizing mechanical compression on the atrioventricular conduction system. Additionally, abolishing systolic backflow into the venae cavae immediately decompresses the systemic venous circulation and augments effective forward stroke volume. As a result, end-organ perfusion rapidly improves following successful device deployment.

Current Device Landscape and Clinical Evidence

The device landscape for transcatheter tricuspid therapy has expanded rapidly across international structural heart centers. Transfemoral orthotopic systems, notably the EVOQUE system, have gained regulatory approval following landmark clinical trials. Specifically, the pivotal TRISCEND II randomized trial demonstrated that transcatheter replacement combined with medical therapy was superior to medical therapy alone. Treated patients achieved near-complete elimination of regurgitation, significant reductions in heart failure hospitalizations, and dramatic quality-of-life gains.

Furthermore, transjugular and transatrial systems, such as the LuX-Valve, utilize unique non-radial anchoring to treat complex anatomies. In patients with prohibitive right ventricular dysfunction, heterotopic bicaval valve systems prevent caval reflux. Consequently, real-world registry data confirm technical success rates exceeding ninety-five percent across diverse patient populations. Moreover, clinical improvements remain sustained during extended multicenter post-market surveillance follow-up.

Preprocedural Imaging Guidance and Anatomical Sizing

Comprehensive multimodality imaging is indispensable for candidate selection and procedural guidance. Transthoracic and transesophageal echocardiography establish baseline regurgitation severity, assess right ventricular function, and evaluate pulmonary hemodynamics. Because acoustic shadowing can hinder transesophageal visualization, operators routinely use real-time intracardiac echocardiography for precise device positioning and deployment.

Additionally, electrocardiogram-gated multidetector computed tomography provides crucial three-dimensional anatomical evaluation. Preprocedural computed tomography precisely quantifies annular dimensions, evaluates leaflet geometry, and maps right coronary artery proximity. Furthermore, clinicians evaluate distance to the atrioventricular node to anticipate conduction complications. Right heart catheterization also remains necessary to rule out severe post-capillary pulmonary hypertension. Together, these imaging modalities enable meticulous device sizing and minimize paravalvular regurgitation risks. In addition, detailed anatomical planning ensures optimal subvalvular anchor engagement without entrapping chordal structures.

Procedural Challenges and Antithrombotic Management

Despite excellent technical success, transcatheter tricuspid replacement involves specific clinical challenges. Conduction disturbances represent a prominent complication because radial forces near the triangle of Koch can induce complete heart block. Consequently, up to fifteen percent of patients require permanent pacemaker implantation. Heart teams proactively plan leadless or coronary sinus pacing strategies to mitigate this issue.

Another critical challenge involves acute right ventricular afterload mismatch. Eliminating severe regurgitation immediately forces the right ventricle to pump its full volume against pulmonary resistance, which may cause transient right ventricular dysfunction. Furthermore, antithrombotic management requires careful balancing. Given the low-pressure, low-velocity right atrial environment, clinicians generally prescribe oral anticoagulation for at least three to six months to prevent bioprosthetic valve thrombosis. Therefore, tailored post-procedural surveillance protocols optimize long-term clinical safety and hemodynamic stability.

Future Perspectives in Transcatheter Tricuspid Valve Replacement

The future of transcatheter tricuspid therapy focuses on refining device profiles, clarifying timing, and determining bioprosthetic durability. Ongoing clinical trials will establish definitive comparative evidence between transcatheter replacement and edge-to-edge repair strategies. Moreover, next-generation delivery systems with lower profile diameters will facilitate easier transfemoral venous navigation.

Crucially, earlier clinical intervention remains the primary objective. Treating patients before the onset of irreversible right ventricular fibrosis, severe secondary pulmonary hypertension, or advanced cirrhosis ensures optimal clinical recovery. Advanced computational modeling and artificial intelligence will further refine patient selection algorithms. In addition, long-term registries will provide vital durability benchmarks for bioprosthetic leaflets. Ultimately, transcatheter tricuspid replacement is poised to transform severe tricuspid regurgitation from an intractable terminal condition into a safely treatable structural disorder.

Frequently Asked Questions

How does transcatheter tricuspid valve replacement differ from edge-to-edge repair?

Transcatheter tricuspid replacement implants an entire prosthetic bioprosthesis within the native tricuspid annulus, which completely eliminates regurgitant blood flow. In contrast, transcatheter edge-to-edge repair clips native leaflets together to reduce the regurgitant orifice area. Consequently, replacement provides a more definitive therapeutic solution for patients presenting with massive coaptation gaps, pacemaker lead impingement, or severely tethered leaflets where anatomical grasping remains technically unfeasible or inadequate.

What are the primary complications associated with transcatheter tricuspid replacement?

The most common clinical complications include cardiac conduction disturbances, such as high-grade atrioventricular block necessitating permanent pacemaker implantation. Additionally, patients face risks of vascular access bleeding, early bioprosthetic valve thrombosis, and transient right ventricular decompensation caused by sudden afterload increases. Heart teams actively mitigate these clinical risks through meticulous preprocedural multimodality imaging planning, disciplined patient selection criteria, and structured post-procedural antithrombotic regimens.

Which patients benefit most from transcatheter tricuspid valve replacement?

Symptomatic patients with severe, massive, or torrential tricuspid regurgitation who demonstrate prohibitive open-surgical risk benefit most from transcatheter replacement. Furthermore, optimal candidates possess suitable annular dimensions, preserved or mildly impaired right ventricular systolic function, and an absence of severe pulmonary hypertension. Timely clinical referral ensures maximum hemodynamic improvement, preventing irreversible right ventricular remodeling along with severe secondary hepatic and renal dysfunction.

Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Calamita G et al. Transcatheter tricuspid valve replacement for severe tricuspid regurgitation: current and future perspectives. Expert Rev Med Devices. 2026 Aug 29. doi: 10.1080/17434440.2026.2713742. PMID: 42667674.

2. Kodali S, Hahn RT, Davidson CJ, et al. Transcatheter Tricuspid-Valve Replacement for Severe Tricuspid Regurgitation: TRISCEND II Randomized Trial. N Engl J Med. 2024;391(24):2275-2286.

3. Grayburn PA, Lurz P, Adamo M, et al. TRISCEND II: Novel Randomized Trial Design for Transcatheter Tricuspid Valve Replacement. Am J Cardiol. 2024;225:124-131.

4. Makkar R, Fam N, von Ballmoos MW, et al. Real-World Outcomes of Transcatheter Tricuspid Valve Replacement: Analysis From the STS/ACC TVT Registry. JAMA. 2026;335(15):1480-1491.